SCHEMBL7797624

SCHEMBL7797624

C=CCc1cc2c(cc1[O])OCO2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.53
CYP1A2 P05177 2/20 0.53
MAPT P10636 1/20 0.53
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
POLB P06746 3/20 0.40
ALOX15 P16050 1/20 0.39
GABRA1 P14867 1/20 0.36
GABRB2 P47870 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.35
PTPN1 P18031 1/20 0.34
SRD5A1 P18405 1/20 0.34
GAA P10253 1/20 0.34
CYP2D6 P10635 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1276635 0.78 CYP3A4 (0.55) CYP3A4CYP1A2MAPTALDH1A1SMN1; SMN2
SCHEMBL21363791 0.77 CYP3A4 (0.53) CYP3A4CYP1A2MAPTALDH1A1SMN1; SMN2
SCHEMBL11696893 0.77 CYP3A4 (0.53) CYP3A4CYP1A2MAPTALDH1A1SMN1; SMN2
SCHEMBL11498272 0.73 CYP3A4 (0.49) CYP3A4CYP1A2MAPTALDH1A1SMN1; SMN2
SCHEMBL14552371 0.73 POLB (0.61) CYP3A4CYP1A2MAPTALDH1A1SMN1; SMN2
SCHEMBL11699301 0.72 CYP3A4 (0.47) CYP3A4CYP1A2MAPTALDH1A1SMN1; SMN2
SCHEMBL21363749 0.71 CYP3A4 (0.43) CYP3A4CYP1A2MAPTALDH1A1SMN1; SMN2
SCHEMBL21363755 0.71 MAPT (0.43) CYP3A4CYP1A2MAPTALDH1A1SMN1; SMN2
Safrole SCHEMBL29368306 0.69 CYP3A4 (1.00) CYP3A4CYP1A2MAPTALDH1A1SMN1; SMN2
Safrole SCHEMBL56828 0.69 CYP3A4 (1.00) CYP3A4CYP1A2MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010014694-A1 Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin ENCYSIVE PHARMACEUTICALS, INC. 2001-08-16 US disclosed
US-6265428-B1 VASODILATION TEXAS BIOTECHNOLOGY CORPORATION 2001-07-24 US disclosed
US-5977117-A Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin TEXAS BIOTECHNOLOGY CORPORATION (US) 1999-11-02 US disclosed
EP-0876364-A2 SUBSTITUTED PHENYL COMPOUNDS AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1998-11-11 EP disclosed
WO-1997025321-A2 SUBSTITUTED PHENYL COMPOUNDS AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1997-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010014694-A1 Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin EDNRA, EDNRB, NPR1 CYP3A4 1334/4885CYP1A2 1124/4885MAPT 4496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.